Premium
Bench to Bedside : Pathophysiology of Acute Coronary Syndromes and Implications for Therapy
Author(s) -
Brogan Gerard X.
Publication year - 2002
Publication title -
academic emergency medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.221
H-Index - 124
eISSN - 1553-2712
pISSN - 1069-6563
DOI - 10.1197/aemj.9.10.1029
Subject(s) - medicine , antithrombotic , acute coronary syndrome , unstable angina , pathophysiology , myocardial infarction , cardiology , fibrinolytic agent , intensive care medicine , thrombosis
Our understanding of the pathophysiology of unstable angina (UA) and non—ST‐segment elevation (NSTE) myocardial infarction (MI) [commonly referred to as NSTE acute coronary syndrome(s) (ACS)] has evolved considerably over the years, with atherothrombosis playing a pivotal role. This review discusses the molecular interactions in coronary thrombosis that may serve as therapeutic targets for more effective management of these syndromes. The purposes of this review are: 1) to discuss current understanding of the pathophysiology of NSTE ACS; 2) to describe recent studies with novel antithrombotic agents [e.g., low‐molecular‐weight heparin, thienopyridines, glycoprotein (GP) IIb‐IIIa inhibitors] in patients with NSTE ACS; and 3) to highlight recommendations for management of patients with NSTE ACS in the recently updated American College of Cardiology (ACC)/ American Heart Association (AHA) guidelines, including the appropriate use of antithrombotic therapies.